Skip to main content

Canada authorizes AstraZeneca's drug for COVID prevention

Share

Canada on Thursday authorized British drugmaker AstraZeneca Plc's AZN.L antibody-based therapy for preventing COVID-19 infections, giving itself another weapon against the disease as cases rise in the country.

Health Canada has cleared the drug - Evusheld - for use in individuals aged 12 years and older who are immune compromised and unlikely to mount an adequate immune response to COVID-19 vaccination or for whom COVID-19 vaccination is not recommended.

While vaccines rely on an intact immune system to develop targeted antibodies and infection-fighting cells, Evusheld contains lab-made antibodies designed to linger in the body for months to contain the virus in case of an infection.

The therapy has already been authorized in the United States and its use has also been recommended by the European Medicines Agency.

CTVNews.ca Top Stories

Nylander defends Leafs' core after playoff exit, Toronto again picks up the pieces

William Nylander stood in a solemn visitors locker room at TD Garden just before midnight. The Maple Leafs had battled back from a 3-1 series deficit against the Boston Bruins with consecutive 2-1 victories - including one that required extra time - in their first-round playoff series to push the club's Original Six rival to the limit before suffering a devastating Game 7 overtime loss. Nylander's message was emphatic.

Local Spotlight

Stay Connected